ENSA抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09983(ENSA Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human tonsil tissue using P09983(ENSA Antibody) at dilution 1/40. (Original magnification: ×200)    

  
  

ENSA (Endosulfine Alpha) is a highly conserved, ubiquitously expressed protein encoded by the *ENSA* gene. It plays a dual role in cellular regulation, primarily through its interaction with Protein Phosphatase 2A (PP2A), a key enzyme in signal transduction. ENSA binds and inhibits PP2A activity, modulating processes like cell cycle progression, insulin secretion, and cardiac ion channel function. Structurally, ENSA contains a PP1/PP2A inhibitory domain and undergoes phosphorylation-dependent conformational changes, enabling dynamic regulation of PP2A during mitosis.

ENSA is implicated in diverse pathologies. In diabetes, aberrant ENSA expression disrupts insulin granule exocytosis. In cancer, its overexpression correlates with uncontrolled proliferation via PP2A suppression. Notably, ENSA mutations are linked to Brugada syndrome, a cardiac arrhythmia disorder, due to altered sodium channel regulation.

Antibodies targeting ENSA are vital research tools, enabling detection of its expression, localization, and post-translational modifications in models ranging from cell lines to tissues. These antibodies aid in studying ENSA’s role in disease mechanisms and its potential as a therapeutic target. Recent studies explore ENSA inhibitors for cancer and metabolic disorders, highlighting its clinical relevance. However, ENSA’s pleiotropic functions necessitate context-specific investigation to avoid off-target effects in therapeutic applications.